Factors Affecting the Price of Bavencio

Avelumab (Bavencio) is a PD-L1 immune checkpoint inhibitor co-developed by Pfizer and Merck. It was approved by the FDA in 2017 for the treatment of metastatic Merkel cell carcinoma (MCC) and locally advanced/metastatic urothelial carcinoma (UC). As a humanized monoclonal antibody, it relieves tumor immune escape by blocking the PD-1/PD-L1 pathway and activates T cells to attack cancer cells.